Arcutis Biotherapeutics Inc
ARQT
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.16B
Close$
$-28.99
212.3% downside
Current Fair Value
212.3% downsideOvervalued by 212.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.16 Billion |
|---|---|
| Enterprise Value | $3.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 1.48 |
| Outstanding Shares | 130,522,000 |
Return
| Return on Equity | 12.93% |
|---|---|
| Return on Assets | 5.84% |
| Return on Invested Capital | 11.86% |
Valuation & Multiples
| P/E Ratio | 114.54 |
|---|---|
| PEG | -58.89 |
| Price to Sales | 8.61 |
| Price to Book Ratio | 25.83 |
| Enterprise Value to Revenue | 6.99 |
| Enterprise Value to EBIT | 83.33 |
| Enterprise Value to Net Income | 113 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$118.85 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$141.02 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.58% |
|---|---|
| Total Calls | 1,400▼ 99.58% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.29%▼ 80.91% |
|---|---|
| Total Invested | $722.32M▼ 76.81% |
| Investors Holding | 89▼ 188.00% |
ESG Score
No data